American Medical Association creates its own vaccine safety, effectiveness review system

The American Medical Association announced Tuesday the launch of its own “evidence-based review process” of vaccine safety and efficacy for the next respiratory virus season.

The move comes after the Advisory Committee on Immunization Practices for the Centers for Disease Control and Prevention voted to stop recommending infants receive the hepatitis B shot at birth, and the measles, mumps, rubella and chicken pox vaccine.

The AMA’s evaluation will be done in collaboration with the Vaccine Integrity Project at the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and will focus on COVID-19, flu and RSV vaccines.

“Respiratory viruses hospitalize and kill tens of thousands of Americans every year, and vaccine decisions must be guided by facts, not politics or ideology,” CIDRAP Director Michael Osterholm said in a statement. “Our goal is to build on our efforts to restore peace of mind for clinicians and patients by ensuring that experts are continuously evaluating vaccine safety and effectiveness using transparent, evidence-based methods.”

The AMA represents more than 270,000 members and said it will meet with “leading medical professional societies" to determine important policy questions. 

Misty Severi is a news reporter for Just The News. You can follow her on X for more coverage.